PROBLEM

Blocked access to the left heart by structural hear septal occluders preventing ischemic stroke.

INNOVATIVE SOLUTION

Developing a family of structural heart occlusion devices allowing easy re-access to the left heart for large bore trans-septal devices.

• I-Atrogenic (I-ASD) Atrial Septal Defect Closure Device
• Patent Foremen Ovale (PFO) Closure Device
• Left Atrial Appendage (LAA) Closure and Sizing Device

INVESTMENT OPPORTUNITY

Market size: $1B

TARGET EXIT STRATEGY

PROBLEM

Sensitive and specific diagnostic, imaging and therapeutic options for deadly cancers like glioblastoma do not exist.

INNOVATIVE SOLUTION

Highly targeted, stable aptamers allow us to bind glioblastoma stem cells, and will lead to screening blood tests, theragnostics and payload delivery for better outcomes.

INVESTMENT OPPORTUNITY

Market size: $4.2B (by 2028)

TARGET EXIT STRATEGY

M&A in 2028: $450M

PROBLEM

60% post ischemic stroke treatment disability.

INNOVATIVE SOLUTION

Developing the first device to treat ischemic stroke in first pass (time saving = reduced mortality/disability rates) and more effectively (targeting soft, medium, and hard clots that currently are an unmet need).

INVESTMENT OPPORTUNITY

Market size: $1B (by 2028)

TARGET EXIT STRATEGY

M&A in 2027: $350M